Procter & Gamble

L Catterton has signed a definitive agreement to sell Thorne to Procter & Gamble for a cash price of $3.8 billion. L Catterton entered Thorne in October 2023, strengthened leadership, marketing, sales, R&D and technological infrastructure, and promoted AI-enabled offerings. The transaction is expected to close in the fourth quarter of 2026; Perella Weinberg Partners and Canaccord Genuity advised Thorne, and Kirkland & Ellis and Jones Day acted as legal counsel. » More on de.investing.com

Procter & Gamble has signed a definitive agreement to acquire Thorne. Thorne produces dietary supplements and AI-powered wellness solutions, operates a factory in South Carolina, and supplies more than seven million consumers as well as medical professionals and professional sports teams. The seller is the Flagship Fund of L Catterton; the deal is expected to close later this year and financial terms were not disclosed. » More on de.investing.com

HSBC downgraded Procter & Gamble from 'buy' to 'hold' and cut the price target from $182 to $149, saying reinvestments in marketing and innovation have so far produced neither volume growth nor margin improvements. P&G reported fourth-quarter sales of $21.2 billion and adjusted EPS of $1.43, slightly above consensus, while adjusted operating income missed estimates due to higher selling and marketing costs. HSBC views organic sales as weak and has reduced earnings estimates for 2027–2029 as well as valuation multiples; P&G expects fiscal 2027 revenue growth of 1–3% and plans about $10 billion in dividends and $5 billion in share buybacks. » More on de.investing.com